Andy Plump

Money Moves

Retiring June 2027; leading R&D until successor is named

Andy Plump, who rebuilt Takeda's drug pipeline over 12 years and steered the $62 billion Shire acquisition, will retire as president of R&D in June 2027. He announced the plan on September 10 but stays until a successor is named.

Updated Yesterday

New Capabilities

Leading regulatory push and broader immunology expansion strategy

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated May 15